Early Metabolic Markers of the Development of Dysglycemia and Type 2 Diabetes and Their Physiological Significance
- Ele Ferrannini1,
- Andrea Natali1,
- Stefania Camastra1,
- Monica Nannipieri1,
- Andrea Mari2,
- Klaus-Peter Adam3,
- Michael V. Milburn3,
- Gabi Kastenmüller4,
- Jerzy Adamski5,
- Tiinamaija Tuomi6,7,
- Valeriya Lyssenko8,
- Leif Groop8 and
- Walter E. Gall3
- 1Department of Internal Medicine, University of Pisa School of Medicine, Pisa, Italy
- 2National Research Council Institute of Biomedical Engineering, Padua, Italy
- 3Metabolon, Inc., Durham, North Carolina
- 4Institute of Bioinformatics and Systems Biology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany
- 5Institute of Experimental Genetics, Genome Analysis Center, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany
- 6Department of Medicine, Helsinki University Central Hospital, and Research Program of Molecular Medicine, University of Helsinki, Helsinki, Finland
- 7Folkhalsan Research Centre, Helsinki, Finland
- 8Department of Clinical Sciences, Diabetes and Endocrinology, Lund University, Malmö, Sweden
- Corresponding author: Walter E. Gall, .
Metabolomic screening of fasting plasma from nondiabetic subjects identified α-hydroxybutyrate (α-HB) and linoleoyl-glycerophosphocholine (L-GPC) as joint markers of insulin resistance (IR) and glucose intolerance. To test the predictivity of α-HB and L-GPC for incident dysglycemia, α-HB and L-GPC measurements were obtained in two observational cohorts, comprising 1,261 nondiabetic participants from the Relationship between Insulin Sensitivity and Cardiovascular Disease (RISC) study and 2,580 from the Botnia Prospective Study, with 3-year and 9.5-year follow-up data, respectively. In both cohorts, α-HB was a positive correlate and L-GPC a negative correlate of insulin sensitivity, with α-HB reciprocally related to indices of β-cell function derived from the oral glucose tolerance test (OGTT). In follow-up, α-HB was a positive predictor (adjusted odds ratios 1.25 [95% CI 1.00–1.60] and 1.26 [1.07–1.48], respectively, for each standard deviation of predictor), and L-GPC was a negative predictor (0.64 [0.48–0.85] and 0.67 [0.54–0.84]) of dysglycemia (RISC) or type 2 diabetes (Botnia), independent of familial diabetes, sex, age, BMI, and fasting glucose. Corresponding areas under the receiver operating characteristic curve were 0.791 (RISC) and 0.783 (Botnia), similar in accuracy when substituting α-HB and L-GPC with 2-h OGTT glucose concentrations. When their activity was examined, α-HB inhibited and L-GPC stimulated glucose-induced insulin release in INS-1e cells. α-HB and L-GPC are independent predictors of worsening glucose tolerance, physiologically consistent with a joint signature of IR and β-cell dysfunction.
- Received May 29, 2012.
- Accepted September 4, 2012.
- © 2013 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.